Premium
Bcl‐X expression in esophageal squamous cell carcinoma: Association with tumor progression and prognosis
Author(s) -
Takayama Tomoyoshi,
Nagao Mitsuo,
Sawada Hidetomo,
Yamada Yukishige,
Emoto Kouji,
Fujimoto Heisuke,
Ueno Masato,
Hirao Shuya,
Nakajima Yoshiyuki
Publication year - 2001
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.1130
Subject(s) - immunohistochemistry , medicine , esophageal squamous cell carcinoma , tumor progression , basal cell , oncology , carcinoma , cancer research , pathology , cancer
Background and Objectives: Bcl‐2 family proteins are regulators of programmed cell death and important in the development and progression of human various tumors. The role of these proteins in the development, progression and differentiation of esophageal squamous cell carcinoma (ESCC) is unclear. Methods: We investigated the expression of Bcl‐2, Bcl‐X, and Bax using immunohistochemistry in 86 ESCCs, and scored the expression by the weighted score. Results: Bcl‐2 expression related to pT category ( P =0.043) and histological grade ( P = 0.001). Bcl‐X expression related to pT category ( P = 0.003), pN category ( P = 0.041) and the number of positive nodes ( P = 0.036), and had a tendency to relate to histological grade ( P = 0.086). Bax expression had a tendency to relate to pN category ( P = 0.081). The inverse relationship between Bcl‐2 and Bcl‐X expression was detected ( P = 0.001), while the positive one between Bcl‐X and Bax expression was detected ( P = 0.014). Patients with low Bcl‐X weighted score had a significantly longer survival compared with those with high Bcl‐X weighted score. Multivariate analysis revealed Bcl‐X expression as the independent prognostic factors ( P = 0.022). Conclusion: These results imply that Bcl‐2 family proteins, especially Bcl‐X, may contribute to the progression in ESCC. J. Surg. Oncol. 2001;78:116–123. © 2001 Wiley‐Liss, Inc.